Aglaris is a technology developer and provider that focuses on novel technologies for cell therapy manufacturing. Aglaris’ proprietary and transformative technology addresses critical weaknesses in the process development and manufacturing of T cell and other cell-based therapeutics. On top of its high-performance cell culture geometry, Aglaris is delivering CMC / PAT / Real-time Monitoring & Management to cell manufacturing. Both things together define a new generation of autonomous cell manufacturing equipment.

The company is led by industry experts, Mr. Steve Docksey, Dr David Horna and Dr Miquel Costa, who manage a growing international team with top engineers and scientists. Aglaris is located in state-of-the-art facilities and equipment at two technology parks: Stevenage Bioscience Catalyst in Stevenage, UK, and QUBE Technology Park in Madrid, Spain.

SCTbio is a European global contract development and manufacturing organization for Advanced Therapy Medicinal Products (ATMPs). Founded in July 2021 as a spin-off from SOTIO, member of PPF Group, to directly address the growing demand for cell and gene therapy manufacturing, SCTbio holds over a decade of experience developing best-in-class clinical manufacturing services, development solutions and technologies transfer.

Pall corporation offers integrated end-to-end bioprocessing solutions for gene therapy, from early process development projects to commercialization. Our dedicated experts will work with you to overcome development and viral vector manufacturing obstacles to accelerate delivery of commercially viable gene therapies to patients. Our extensive portfolio of upstream, downstream, and formulation and filling technologies is suitable for manufacturing different viral vector types in adherent or suspension-based processes.  Whether that means quickly developing a process, helping you ensure regulatory compliance, or making existing processes easier and more effective, we are ready to work with you to accelerate your speed to market.